Why the study?
Preclinical studies and manufacturing of a clinical coxsackievirus B vaccine are underway to enable clinical testing for type 1 diabetes.
Manufacturing and preclinical studies are currently in progress to enable clinical testing of the first coxsackievirus B vaccine for type 1 diabetes.
Supports progression of the first coxsackievirus B vaccine toward human trials for type 1 diabetes prevention; leaves open its clinical efficacy and safety.
Manufacturing of a clinical CVB vaccine as well as preclinical studies are currently in progress in order to enable clinical testing of the first CVB vaccine. Ongoing scientific research projects can significantly facilitate this effort by providing insights into the mechanisms of the CVB-T1D association.
No takes yet. Share an insight, caveat, or question.
Hyöty et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: